[{"address1": "1 North Waukegan Road", "city": "North Chicago", "state": "IL", "zip": "60064-6400", "country": "United States", "phone": "847 932 7900", "website": "https://www.abbvie.com", "industry": "Drug Manufacturers - General", "industryKey": "drug-manufacturers-general", "industryDisp": "Drug Manufacturers - General", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Beh\u00e7et's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Richard A. Gonzalez", "age": 70, "title": "Executive Chairman", "yearBorn": 1954, "fiscalYear": 2023, "totalPay": 7190594, "exercisedValue": 0, "unexercisedValue": 47864680}, {"maxAge": 1, "name": "Mr. Robert A. Michael CPA", "age": 54, "title": "CEO & Director", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 4616880, "exercisedValue": 0, "unexercisedValue": 15390147}, {"maxAge": 1, "name": "Mr. Scott T. Reents", "age": 57, "title": "Executive VP & CFO", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 3132761, "exercisedValue": 0, "unexercisedValue": 5589906}, {"maxAge": 1, "name": "Dr. Azita  Saleki-Gerhardt Ph.D.", "age": 61, "title": "Executive VP & COO", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 3510428, "exercisedValue": 5248500, "unexercisedValue": 23376292}, {"maxAge": 1, "name": "Mr. Jeffrey Ryan Stewart", "age": 55, "title": "Executive VP & Chief Commercial Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 4315363, "exercisedValue": 2125307, "unexercisedValue": 9617938}, {"maxAge": 1, "name": "Dr. Roopal  Thakkar M.D.", "age": 52, "title": "Executive VP of Research and Development & Chief Scientific Officer", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Elizabeth  Shea", "title": "Senior Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Perry C. Siatis", "age": 49, "title": "Executive VP, General Counsel & Secretary", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sanjay  Narayan", "title": "Senior VP, Chief Ethics, Compliance Officer & Allergan Aesthetic Legal", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Timothy J. Richmond", "age": 58, "title": "Executive VP & Chief Human Resources Officer", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 1121841, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 4, "compensationRisk": 3, "shareHolderRightsRisk": 9, "overallRisk": 7, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 193.45, "open": 193.95, "dayLow": 192.78, "dayHigh": 195.18, "regularMarketPreviousClose": 193.45, "regularMarketOpen": 193.95, "regularMarketDayLow": 192.78, "regularMarketDayHigh": 195.18, "dividendRate": 6.56, "dividendYield": 0.034, "exDividendDate": 1744675200, "payoutRatio": 2.5941, "fiveYearAvgDividendYield": 4.08, "beta": 0.561, "trailingPE": 80.69874, "forwardPE": 13.9394, "volume": 3973852, "regularMarketVolume": 3973852, "averageVolume": 6068771, "averageVolume10days": 5232070, "averageDailyVolume10Day": 5232070, "bid": 192.94, "ask": 193.88, "bidSize": 2900, "askSize": 900, "marketCap": 340828291072, "fiftyTwoWeekLow": 153.58, "fiftyTwoWeekHigh": 207.32, "priceToSalesTrailing12Months": 6.0501347, "fiftyDayAverage": 178.9836, "twoHundredDayAverage": 180.23795, "trailingAnnualDividendRate": 6.29, "trailingAnnualDividendYield": 0.032514863, "currency": "USD", "enterpriseValue": 404905361408, "profitMargins": 0.07594, "floatShares": 1763994813, "sharesOutstanding": 1767139968, "sharesShort": 18931401, "sharesShortPriorMonth": 17003576, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0107, "heldPercentInsiders": 0.00491, "heldPercentInstitutions": 0.73882, "shortRatio": 3.11, "shortPercentOfFloat": 0.0107, "impliedSharesOutstanding": 1767139968, "bookValue": 3.413, "priceToBook": 56.5104, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": 4278000128, "trailingEps": 2.39, "forwardEps": 12.13, "enterpriseToRevenue": 7.188, "enterpriseToEbitda": 15.167, "52WeekChange": 0.09741104, "SandP52WeekChange": 0.22894537, "lastDividendValue": 1.64, "lastDividendDate": 1736899200, "exchange": "NYQ", "quoteType": "EQUITY", "symbol": "ABBV", "underlyingSymbol": "ABBV", "shortName": "AbbVie Inc.", "longName": "AbbVie Inc.", "firstTradeDateEpochUtc": 1357137000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "73238d42-cdcc-3f92-8141-dd675addae10", "messageBoardId": "finmb_141885706", "gmtOffSetMilliseconds": -18000000, "currentPrice": 192.87, "targetHighPrice": 239.0, "targetLowPrice": 165.0, "targetMeanPrice": 204.89555, "targetMedianPrice": 210.0, "recommendationMean": 1.92857, "recommendationKey": "buy", "numberOfAnalystOpinions": 27, "totalCash": 7285000192, "totalCashPerShare": 4.122, "ebitda": 26695663616, "totalDebt": 71323000832, "totalRevenue": 56334000128, "debtToEquity": 1174.815, "revenuePerShare": 31.773, "returnOnEquity": 0.52052, "grossProfits": 39654998016, "revenueGrowth": 0.056, "grossMargins": 0.70392996, "ebitdaMargins": 0.47388, "operatingMargins": 0.3134, "financialCurrency": "USD", "trailingPegRatio": 2.5832, "__fetch_time": "2025-02-15"}]